OBP 801

Drug Profile

OBP 801

Alternative Names: OBP-801; YM 753

Latest Information Update: 16 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Oncolys BioPharma
  • Class Cyclic peptides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal cancer
  • Discontinued Haematological malignancies; Mesothelioma; Pancreatic cancer

Most Recent Events

  • 16 Apr 2015 Discontinued - Preclinical for Haematological malignancies in Japan (unspecified route)
  • 16 Apr 2015 Discontinued - Preclinical for Mesothelioma in Japan (unspecified route)
  • 16 Apr 2015 Discontinued - Preclinical for Pancreatic cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top